Skip to main content
. Author manuscript; available in PMC: 2015 Jul 6.
Published in final edited form as: Nature. 2014 Jul 27;513(7516):65–70. doi: 10.1038/nature13485

Figure 2. Silvestrol has single-agent activity against T-ALL.

Figure 2

a) Reporter system with capped renilla luciferase (red) and firefly luciferase under the HCV IRES (black); (below) Relative levels of renilla luciferase (red) and firefly (black) luciferase upon vehicle (DMSO), Silvestrol, or (±)-CR-31-B. Mean/SD, n = 3 biological replicates; b) Viability of primary patient T-ALL samples treated with Silvestrol (48 h; mean/SD of 4 replicates; c) Tumour size of KOPT-K1 xenografts treated with (±)-CR-31-B (0.2 mg/kg) or vehicle, mean/SD of 5 tumors; d) Immunohistochemical analysis of (±)-CR-31-B treated KOPT-K1 tumours; e) Diagram of drug targets; f) Lysates of KOPT-K1 cells treated with vehicle (Veh), Rapamycin (Rapa: 25 nM), (±)-CR-31-B (CR: 25 nM), or Silvestrol (Silv: 25 nM) for 48 hours and probed as indicated.